Skip to main content

Berkeley Lights to Showcase its Optofluidic Discovery Technology at 2021 Antibody Engineering & Therapeutics Conference

Written by Customer Service on . Posted in Public Companies.

Genovac, a top contract research and manufacturing organization, to report new single B-cell service offerings and GPCR campaign results achieved from the Berkeley Lights Beacon® Optofluidic System for antibody discovery

EMERYVILLE, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced its participation at the upcoming Antibody Engineering & Therapeutics (AE&T) meeting, being held virtually and in person from Dec. 12-16, 2021, in San Diego, California. During the AE&T meeting, the latest antibody science, technologies and academic and industry partners come together to accelerate next-generation antibodies towards commercial success.

Berkeley Lights will showcase its Beacon Optofluidic System and single B-cell antibody discovery workflow at AE&T booth #305. Meeting participants who visit the Berkeley Lights booth can receive a demonstration of the Beacon System performing the Opto™ Plasma B Discovery (OPBD) 4.0 workflow, which enables recovery of 1000s of hits by screening up to 100,000 plasma B cells and the down-selection of lead candidates with functional assays, which can then be sequenced to realize the re-expression of >1000 functionally characterized antibodies in just one week. By maximizing the diversity through direct functional profiling of plasma B cells, the OPBD 4.0 workflow allows users to accelerate discovery against even the most challenging targets.

Presentation by Genovac
Amelie Kutschera, MSc., single B-cell scientist at Genovac, will deliver a presentation entitled “Leading Strategies for Antibody Discovery Against Difficult Targets –Genetic Immunization and Berkeley Lights Beacon®,” Wednesday, December 15 from 12:00 p.m. – 12:30 p.m. PT. Kutschera will discuss how traditional hybridoma and phage display methods have shown limited success in delivering therapeutic antibodies against difficult targets and share how Genovac has overcome this challenge by leveraging their proprietary genetic immunization technology and Berkeley Lights’ Beacon Optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.  

About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.

Berkeley Lights’ Beacon® and Lightning™ systems and Culture Station™ instrument are FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company’s growth and continual evolution see the statements in the “Risk Factors” sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission.

Media Contacts
media @berkeleylights.com
info@genovac.com

Investor Contact
IR@berkeleylights.com

 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.